These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 16107833)

  • 21. Hepatitis C virus and antiviral innate immunity: who wins at tug-of-war?
    Yang DR; Zhu HZ
    World J Gastroenterol; 2015 Apr; 21(13):3786-800. PubMed ID: 25852264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of HIV on host-virus interactions during early hepatitis C virus infection.
    Danta M; Semmo N; Fabris P; Brown D; Pybus OG; Sabin CA; Bhagani S; Emery VC; Dusheiko GM; Klenerman P
    J Infect Dis; 2008 Jun; 197(11):1558-66. PubMed ID: 18419344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis C: virus, host, disease.
    Ippolito G; Craxi A
    Cell Death Differ; 2003 Jan; 10 Suppl 1():S1-2. PubMed ID: 12655335
    [No Abstract]   [Full Text] [Related]  

  • 24. Mechanism of action of interferon and ribavirin in treatment of hepatitis C.
    Feld JJ; Hoofnagle JH
    Nature; 2005 Aug; 436(7053):967-72. PubMed ID: 16107837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Humoral immune response against hepatitis C virus.
    Burioni R; Mancini N; Canducci F; Carletti S; Grieco A; Perotti M; Serafini G; Berardinelli E; Bighi S; Varaldo PE; Clementi M
    J Biol Regul Homeost Agents; 2003; 17(2):125-7. PubMed ID: 14518709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intra-host genetic heterogeneity of hepatitis C virus and biomedical implications.
    Clementi M
    J Biol Regul Homeost Agents; 2003; 17(2):120-4. PubMed ID: 14518708
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HCV-hepatocellular carcinoma: new findings and hope for effective treatment.
    Dash S; Haque S; Joshi V; Prabhu R; Hazari S; Fermin C; Garry R
    Microsc Res Tech; 2005 Nov; 68(3-4):130-48. PubMed ID: 16276514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis C virus genetic variability in patients undergoing antiviral therapy.
    Cristina J; del Pilar Moreno M; Moratorio G
    Virus Res; 2007 Aug; 127(2):185-94. PubMed ID: 17449128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expressional screening of interferon-stimulated genes for antiviral activity against hepatitis C virus replication.
    Itsui Y; Sakamoto N; Kurosaki M; Kanazawa N; Tanabe Y; Koyama T; Takeda Y; Nakagawa M; Kakinuma S; Sekine Y; Maekawa S; Enomoto N; Watanabe M
    J Viral Hepat; 2006 Oct; 13(10):690-700. PubMed ID: 16970601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective study of viral clearance and CD4(+) T-cell response in acute hepatitis C primary infection and reinfection.
    Aberle JH; Formann E; Steindl-Munda P; Weseslindtner L; Gurguta C; Perstinger G; Grilnberger E; Laferl H; Dienes HP; Popow-Kraupp T; Ferenci P; Holzmann H
    J Clin Virol; 2006 May; 36(1):24-31. PubMed ID: 16483838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Immune evasion mechanisms of hepatitis C virus. Review].
    Porto-Espinoza L; Cuadra-Sánchez C; Moronta R; Monsalve-Castillo F; Callejas-Valero D
    Invest Clin; 2006 Mar; 47(1):71-82. PubMed ID: 16562646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Positive selection of cytotoxic T lymphocyte escape variants during acute hepatitis C virus infection.
    Guglietta S; Garbuglia AR; Pacciani V; Scottà C; Perrone MP; Laurenti L; Spada E; Mele A; Capobianchi MR; Taliani G; Folgori A; Vitelli A; Ruggeri L; Nicosia A; Piccolella E; Del Porto P
    Eur J Immunol; 2005 Sep; 35(9):2627-37. PubMed ID: 16114108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cellular and molecular interactions in coinfection with hepatitis C virus and human immunodeficiency virus.
    Roe B; Hall WW
    Expert Rev Mol Med; 2008 Oct; 10():e30. PubMed ID: 18928579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospects for prophylactic and therapeutic vaccines against hepatitis C virus.
    Feinstone SM; Hu DJ; Major ME
    Clin Infect Dis; 2012 Jul; 55 Suppl 1():S25-32. PubMed ID: 22715210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of T-cell responses against immunodominant epitopes from hepatitis C virus E2 and NS4a proteins.
    Sarobe P; Lasarte JJ; García N; Civeira MP; Borrás-Cuesta F; Prieto J
    J Viral Hepat; 2006 Jan; 13(1):47-55. PubMed ID: 16364082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis C virus inhibits intracellular interferon alpha expression in human hepatic cell lines.
    Zhang T; Lin RT; Li Y; Douglas SD; Maxcey C; Ho C; Lai JP; Wang YJ; Wan Q; Ho WZ
    Hepatology; 2005 Oct; 42(4):819-27. PubMed ID: 16175599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of the genetic restriction of virus-specific T-cell responses in hepatitis C virus infection.
    Neumann-Haefelin C; Thimme R
    Genes Immun; 2007 Apr; 8(3):181-92. PubMed ID: 17230195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Viruses and interferon: a fight for supremacy.
    Katze MG; He Y; Gale M
    Nat Rev Immunol; 2002 Sep; 2(9):675-87. PubMed ID: 12209136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis C virus--biology, host evasion strategies, and promising new therapies on the horizon.
    Qureshi SA
    Med Res Rev; 2007 May; 27(3):353-73. PubMed ID: 16958135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intracellular innate immune cascades and interferon defenses that control hepatitis C virus.
    Horner SM; Gale M
    J Interferon Cytokine Res; 2009 Sep; 29(9):489-98. PubMed ID: 19708811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.